Inactive on SAM.gov — responses were due 2 Jul 2026 · No Set aside used · Office of Assistant Secretary for Preparedness and Response, HHS · Washington, DC · NAICS 541714 · Solicitation RRPV-26-13-BundiVx
Following NAICS 541714? Get new solicitations in it by email as they post — no account needed.
A newer version of this notice has been posted. SAM.gov republished solicitation RRPV-26-13-BundiVx on 18 June 2026. This page is kept because it is a real record, but the current requirement, dates and attachments are on the latest version. Read the latest version →
What happened next
SAM.gov marked this notice inactive — responses were due 02 July 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 541714 (Research and Development in Biotechnology (Except Nanobiotechnology)) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
UPDATE: Question and Answers attached in documents. Date for submission revised to July 2, 2026. The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows: The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks. Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical. The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM. The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development. Please see the attachments for more information. Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern. Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/
Version history
SAM.gov has posted 4 notices under solicitation RRPV-26-13-BundiVx, oldest first.
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
